Compound 6a (Anticancer Agent 171), an oxime analogue, demonstrates anticancer activity by inhibiting HCT116 cells with an IC50 of 3.43 µM and may be utilized for cancer research [1].
Target:
Others
* VAT and and shipping costs not included. Errors and price changes excepted
